<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;October 28, 2004</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>



<hr size=3 noshade width=100%>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=top>

<td width=9%><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;2.02</b></font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2><b>Results of Operations and Financial Condition.</b></font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>


<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On October 28, 2004, Millennium
Pharmaceuticals, Inc. issued a press release to report the company&#146;s financial
results for the quarter ended September 30, 2004. The full text of the press release is
attached to this current report on Form 8-K as Exhibit 99.1. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information in this Form 8-K
shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the company&#146;s financial
position prepared in accordance with generally accepted accounting principles (GAAP). </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Specifically, the attached press
release discusses non-GAAP net loss and non-GAAP profitability, which are non-GAAP
financial measures, and reconciles the company&#146;s historic non-GAAP net loss to its
historic net loss as determined in accordance with GAAP. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $33.5 million in each of the next two years and costs associated with the
company&#146;s 2003 restructuring effort of approximately $5.0 million to $20.0 million in
the aggregate over the next two years, the company is unable to provide a quantitative
reconciliation because the items that would be excluded (which include the types of items
reflected in the reconciliation of historic results) are difficult to predict and estimate
and are primarily dependent on future events.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The company&#146;s management uses these
non-GAAP financial measures to gain a better understanding of the company&#146;s core
operating results and future prospects, consistent with how management measures and
forecasts the company&#146;s performance, especially when comparing such results to
previous periods or forecasts or to those of the company&#146;s competitors. These
measures are also used by the company&#146;s management in their financial and operating
decision-making and for compensation purposes. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These non-GAAP measures exclude
certain non-operational and restructuring charges, non-cash charges and specified other
charges that are included in the most directly comparable GAAP measures. The company
excludes these items because it believes they are outside of the company&#146;s normal
operations and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude: </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
costs associated with the company&#146;s 2003 restructuring effort, such as reducing
overhead and consolidating facilities. The company believes that the costs related to
these restructuring activities are not indicative of the company&#146;s normal operating
costs. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 11 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
company&#146;s newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
costs associated with the company&#146;s debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the
put&nbsp;premiums the company has placed on its convertible notes because the company
considers these costs to be nonoperational and nonrecurring and therefore not necessarily
indicative of the company&#146;s future financial commitments. </FONT></P>







<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>







<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>Date: October 28, 2004&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr noshade size=3>




<p><font face="Times New Roman, Times, Serif" size=2><b><a name="index">EXHIBIT INDEX</a></b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<th width=9% align=center colspan=2><font face="Times New Roman, Times, Serif" size=2>Exhibit No.<br></font><hr noshade></th>
<th width=3%>&nbsp;</th>
<th width=68% align=center><font face="Times New Roman, Times, Serif" size=2>Description<br></font><hr noshade></th>
<th width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></th>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>99.1</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>Press Release of Millennium Pharmaceuticals, Inc.
dated October 28, 2004
</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>




















</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k102804.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11874}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "041100943"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    October 28, 2004
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Item   2.02
Results of Operations and Financial Condition.
On October 28, 2004, Millennium
Pharmaceuticals, Inc. issued a press release to report the company's financial
results for the quarter ended September 30, 2004. The full text of the press release is
attached to this current report on Form 8-K as Exhibit 99.1.
The information in this Form 8-K
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the company's financial
position prepared in accordance with generally accepted accounting principles (GAAP).
Specifically, the attached press
release discusses non-GAAP net loss and non-GAAP profitability, which are non-GAAP
financial measures, and reconciles the company's historic non-GAAP net loss to its
historic net loss as determined in accordance with GAAP. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $33.5 million in each of the next two years and costs associated with the
company's 2003 restructuring effort of approximately $5.0 million to $20.0 million in
the aggregate over the next two years, the company is unable to provide a quantitative
reconciliation because the items that would be excluded (which include the types of items
reflected in the reconciliation of historic results) are difficult to predict and estimate
and are primarily dependent on future events.
The company's management uses these
non-GAAP financial measures to gain a better understanding of the company's core
operating results and future prospects, consistent with how management measures and
forecasts the company's performance, especially when comparing such results to
previous periods or forecasts or to those of the company's competitors. These
measures are also used by the company's management in their financial and operating
decision-making and for compensation purposes.
These non-GAAP measures exclude
certain non-operational and restructuring charges, non-cash charges and specified other
charges that are included in the most directly comparable GAAP measures. The company
excludes these items because it believes they are outside of the company's normal
operations and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude:
•
costs associated with the company's 2003 restructuring effort, such as reducing
overhead and consolidating facilities. The company believes that the costs related to
these restructuring activities are not indicative of the company's normal operating
costs.
•
expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 11 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
company's newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies.
•
costs associated with the company's debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the
put premiums the company has placed on its convertible notes because the company
considers these costs to be nonoperational and nonrecurring and therefore not necessarily
indicative of the company's future financial commitments.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: October 28, 2004
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
3
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of Millennium Pharmaceuticals, Inc.
dated October 28, 2004
4